Stage | Baseline CA19-9 levels | Post CA19-9 levels | P* | Decreased | P†| Decreased > 20% | P†|
---|---|---|---|---|---|---|---|
All patients | 11.23 (6.31, 24.55) | 12.88 (7.24, 24.64) | 0.144 | 209 (39.21) | 0.186 | 142 (26.64) | 0.072 |
0 | 8.87 (5.71, 16.31) | 12.02 (7.51, 18.59) | 0.303 | 10 (29.41) | Â | 5 (14.71) | Â |
I | 9.75 (6.27, 16.88) | 12.58 (7.74, 17.75) | 0.177 | 33 (32.04) | Â | 20 (19.42) | Â |
II | 11.78 (6.56, 23.12) | 12.32 (7.03, 25.09) | 0.619 | 67 (42.14) | Â | 48 (30.19) | Â |
III | 12.15 (6.60, 33.49) | 13.43 (7.17, 27.80) | 0.533 | 99 (41.77) | Â | 69 (29.11) | Â |